A complex pattern of transcriptional control, mRNA stability and post-translational events has been implicated in the control of tissue factor (TF) expression. The goal of this study is to elucidate the multiple molecular mechanisms that bring about the cell-surface expression of this molecule which is responsible for """"""""initiation"""""""" of the coagulation protease cascade by vascular cells (i.e., the monocyte and the endothelial cell). Sequence analysis of the newly isolated human TF gene has identified regions postulated to possess promoter and enhancer activity, including a number of predicted transcription factor binding sites. The cis- acting regulatory regions of the TF gene responsible for transcriptional control, including cell-type-specificity and inducibility by specific agonists, will be mapped by transfection and site-directed mutagenesis. Transfection experiments with unmodified DNA may not reflect all levels of TF gene control; a postulated role for DNA methylation (within and flanking the """"""""HTF island"""""""" region) in the regulation of TF gene activity will also be investigated. Post-transcriptional control will be investigated at the level of TF mRNA turnover. Involvement of protein processing, transit and degradation is hypothesized in regulating the appearance of active TF molecules on the cell surface; these processes will be explored. Understanding how TF expression is regulated in the vascular compartment will be a crucial contribution to understanding normal physiologic regulation of the coagulation system as well as the pathogenesis of intravascular coagulation, the thrombogenic state, and secondary inflammatory responses.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL044225-03
Application #
3363008
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1989-07-01
Project End
1994-06-30
Budget Start
1991-07-01
Budget End
1992-06-30
Support Year
3
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Oklahoma Medical Research Foundation
Department
Type
DUNS #
937727907
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Raskob, G E; Durica, S S; Morrissey, J H et al. (1995) Effect of treatment with low-dose warfarin-aspirin on activated factor VII. Blood 85:3034-9
Bottles, K D; Morrissey, J H (1993) Dexamethasone enhances agonist induction of tissue factor in monocytes but not in endothelial cells. Blood Coagul Fibrinolysis 4:405-14
Morrissey, J H; Macik, B G; Neuenschwander, P F et al. (1993) Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 81:734-44
Disdier, M; Morrissey, J H; Fugate, R D et al. (1992) Cytoplasmic domain of P-selectin (CD62) contains the signal for sorting into the regulated secretory pathway. Mol Biol Cell 3:309-21
Rezaie, A R; Fiore, M M; Neuenschwander, P F et al. (1992) Expression and purification of a soluble tissue factor fusion protein with an epitope for an unusual calcium-dependent antibody. Protein Expr Purif 3:453-60
Fiore, M M; Neuenschwander, P F; Morrissey, J H (1992) An unusual antibody that blocks tissue factor/factor VIIa function by inhibiting cleavage only of macromolecular substrates. Blood 80:3127-34
del Zoppo, G J; Yu, J Q; Copeland, B R et al. (1992) Tissue factor localization in non-human primate cerebral tissue. Thromb Haemost 68:642-7
Neuenschwander, P F; Morrissey, J H (1992) Deletion of the membrane anchoring region of tissue factor abolishes autoactivation of factor VII but not cofactor function. Analysis of a mutant with a selective deficiency in activity. J Biol Chem 267:14477-82
Taylor Jr, F B; Chang, A; Ruf, W et al. (1991) Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 33:127-34
Mackman, N; Fowler, B J; Edgington, T S et al. (1990) Functional analysis of the human tissue factor promoter and induction by serum. Proc Natl Acad Sci U S A 87:2254-8